Trinity Biotech plc (NASDAQ:TRIB – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 18,400 shares, a growth of 70.4% from the June 30th total of 10,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily volume of 52,400 shares, the short-interest ratio is presently 0.4 days.
Trinity Biotech Price Performance
NASDAQ TRIB traded down $0.11 on Friday, reaching $2.88. The stock had a trading volume of 10,558 shares, compared to its average volume of 67,522. The company has a market cap of $21.95 million, a P/E ratio of -1.03 and a beta of 1.31. The firm has a fifty day moving average of $2.34 and a two-hundred day moving average of $2.21. Trinity Biotech has a 1-year low of $1.49 and a 1-year high of $5.10.
Trinity Biotech (NASDAQ:TRIB – Get Free Report) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The business had revenue of $14.70 million for the quarter. Research analysts predict that Trinity Biotech will post -2.17 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Report on Trinity Biotech
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Featured Articles
- Five stocks we like better than Trinity Biotech
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What is the Australian Securities Exchange (ASX)
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.